Photonpharma develops an autologous cell therapy platform, Innocell, designed to treat solid tumor cancers by utilizing patient-derived immune cells to enhance the body's response to recurrent epithelial ovarian cancer. The platform aims to delay disease progression following standard treatments such as chemotherapy, immunotherapy, and surgery, addressing the high mortality rate associated with this cancer type.
Funding
$6.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Recurrent epithelial ovarian cancer has a high mortality rate, and current standard treatments like chemotherapy, immunotherapy, and surgery often fail to prevent disease progression. There is a need for therapies that can effectively delay disease progression and improve survival rates following these initial treatments.
Solution
Photonpharma is developing Innocell, an autologous cell therapy platform designed to treat solid tumor cancers, focusing initially on recurrent epithelial ovarian cancer. Innocell utilizes patient-derived immune cells to enhance the body's immune response against the cancer. The therapy is intended to delay the progression of the disease when used following or in combination with standard treatments like chemotherapy, immunotherapy, radiotherapy, or surgery. By leveraging the patient's own immune cells, Innocell aims to provide a personalized approach to cancer treatment and improve outcomes for patients with recurrent ovarian cancer.
Target Audience
The primary target audience includes patients with recurrent epithelial ovarian cancer who have undergone standard treatments and are seeking therapies to delay disease progression, as well as oncologists and medical professionals specializing in ovarian cancer treatment.
Features
- Autologous cell therapy using patient-derived immune cells.
- Designed to treat solid tumor cancers, with an initial focus on recurrent epithelial ovarian cancer.
- Aims to delay disease progression following standard treatments.
- Phase 1 clinical study FDA cleared to assess safety and immunogenicity in patients with recurrent epithelial ovarian cancer.